FluoroPharma seeks to start US trial of CardioPET molecular imaging agent:
This article was originally published in Clinica
Executive Summary
FluoroPharma has filed with the US FDA its first investigational new drug (IND) application to test its CardioPET molecular imaging agent in a clinical trial. CardioPET is a cardiac viability imaging agent that allows acute and chronic coronary artery disease (CAD) to be assessed while patients are at rest.